195TiP - SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
| Autor: | Maurer, C., Eiger, D., Velghe, C., Aftimos, P.G., Maetens, M., Gaye, J., Paesmans, M., Ignatiadis, M., Piccart, M., Buisseret, L. |
|---|---|
| Zdroj: | In Annals of Oncology May 2019 30 Supplement 3:iii62-iii62 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|